PIK3CA and cancer: By contrast, isoform-specific PI3K inhibitors demonstrate higher efficacy and reduced adverse events by selectively inhibiting individual isoforms and most isoform-specific inhibitors are directed against the p110α catalytic subunit, which is frequently mutated in cancer by PIK3CA mutations [201,202,203].